The Global Sustained Release Excipients Market size is expected to reach $1.9 billion by 2028, rising at a market growth of 8.4% CAGR during the forecast period.
Sustained release excipients are one form of excipient that is added in drugs along with its active pharmacological ingredients. Sustained release excipients are pharmacologically inactive components of the medication formulation. These are formulated with an active ingredient for the purposes of long-term stabilization, bulking up solid mixtures that contain powerful active components in small amounts.
These also refer to a therapeutic improvement on the active component in the concluding dosage form, such as enhancing solubility, facilitating drug absorption, or reducing viscosity. Excipients can also be helpful during the manufacturing process to help with concerns relating to the active substance, such as assisting powder flow properties or non-stick attributes.
Additionally, it supports in vitro stability, such as preventing aggregation or denaturation over the presumed shelf life. The dosage form, mode of administration, the active ingredient, and other variables all play a role in choosing the best excipients. Using polymer layers on solid dosage forms, adding various enzyme-activated systems, polymer matrix technologies, or systems that react to changes in physiological conditions inside the formulation can all result in sustained-release behavior.
Diffusion, dissolution, osmotic pressure, preserving a hydrodynamic or hydrologic equilibrium, and ion exchange are examples of mechanisms. New strategies are currently being explored focused on nanotechnology and innovative matrix technologies, and include buoyant systems, mucoadhesive systems, and gastro-retentive drug distribution for controlled release of antiviral drugs.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include BASF SE, International Flavors & Fragrances, Inc., Ashland Global Holdings Inc., Evonik Industries AG, Croda International Plc, Gattefossé, Merck Group, Pfizer, Inc., Novartis AG and AstraZeneca Plc.
Sustained release excipients are one form of excipient that is added in drugs along with its active pharmacological ingredients. Sustained release excipients are pharmacologically inactive components of the medication formulation. These are formulated with an active ingredient for the purposes of long-term stabilization, bulking up solid mixtures that contain powerful active components in small amounts.
These also refer to a therapeutic improvement on the active component in the concluding dosage form, such as enhancing solubility, facilitating drug absorption, or reducing viscosity. Excipients can also be helpful during the manufacturing process to help with concerns relating to the active substance, such as assisting powder flow properties or non-stick attributes.
Additionally, it supports in vitro stability, such as preventing aggregation or denaturation over the presumed shelf life. The dosage form, mode of administration, the active ingredient, and other variables all play a role in choosing the best excipients. Using polymer layers on solid dosage forms, adding various enzyme-activated systems, polymer matrix technologies, or systems that react to changes in physiological conditions inside the formulation can all result in sustained-release behavior.
Diffusion, dissolution, osmotic pressure, preserving a hydrodynamic or hydrologic equilibrium, and ion exchange are examples of mechanisms. New strategies are currently being explored focused on nanotechnology and innovative matrix technologies, and include buoyant systems, mucoadhesive systems, and gastro-retentive drug distribution for controlled release of antiviral drugs.
COVID-19 Impact Analysis
Due to the closure of R&D and production facilities, the shortage of raw materials, and the lack of a possible workforce, resulting in a decrease in the total movement, including the creation of new items during the lockdown. The pandemic primarily complicated supply chain logistics, driving up the cost of producing different excipients, especially sustained-release excipients. The possibility of sustained release excipients for the production of the COVID-19 vaccine was also still being assessed at the time, taking up the opportunities for other drug development.Market Growth Factors
Increased patient compliance leading to raised comfort
Patient compliance is one of the main issues faced by marketers of pharmaceutical products. A patient's willingness to take medication can significantly decline when it needs to be given multiple times each day, increasing the risk of inadequate treatment. Moreover, studies have stated that an incomplete treatment can aggravate the cause of the disease, leading to high chances of the patient succumbing to the disease again. In such cases of relapse, sometimes medicines become ineffective.Rising disease and disorder prevalence and drug abuse
Globally, both acute and chronic diseases are becoming more common. Significant growth for medications is seen as a result of the rise in chronic disease prevalence. The increasing tendencies of side effects posed by drugs can lead to other problems. Abuse of substances has a significant negative influence on people's and their families’ health. Long-term drug and alcohol addiction can result in mental illness, chronic conditions including diabetes and heart disease, and cancer, all of which place a heavy financial cost on society.Marketing Restraining Factor:
Difficulties in formulations and maintaining API concentration
Attaining optimal dissolution and then release profiles for poor solubility medications, managing the danger of dose dumping, and choosing biocompatible substances with the required controlled-release qualities are only a few of the difficulties that formulators may encounter. High API concentrations, which can occasionally be challenging to manufacture into the appropriate dosage formulations with acceptable characteristics, are also needed for controlled-release pharmaceuticals.
Route of Administration Outlook
On the basis of route of administration, the sustained release excipients market is divided into oral, intramuscular, subcutaneous, transdermal, vaginal, ophthalmic, intravenous, and others. The oral route of administration procured the largest revenue share in the sustained release excipients market in 2021. It is the simplest and most used method of medication delivery. The availability of the highest active surface area enabling drug absorption in contrast to other drug delivery methods is one of the major causes behind the high share. Another significant element that contributes to the widespread adoption of oral drug delivery is the simplicity of producing tablets and capsules.Product Outlook
Based on product, the sustained release excipients market is categorized into gelatin and chitosan, polymers, minerals, sugars, alcohol, and others. The mineral segment witnessed significant revenue share in the sustained release excipients market in 2021. An inorganic substance with a known chemical makeup is a mineral. Minerals can be highly developed products or naturally occurring components or compounds. Calcium carbonate, which is present in limestone, magnesium stearate, which is used as a lubricant, silicon dioxide, which is most frequently associated with beach sand, and many other substances are examples of minerals.Technology Outlook
Based on technology, the sustained release excipients market is segmented into targeted delivery, micro encapsulation, wurster technique, transdermal, implants, coacervation, and others. The targeted delivery technology witnessed the maximum revenue share in the sustained release excipients market in 2021. Targeted delivery entails sending the medication to the desired site of activity and preventing it from going to the wrong portions of the body, which increases the risk of drug toxicity. Higher patient compliance is provided by sustained release drug delivery systems, and localization of the drug is made possible by targeted drug delivery technology.Regional Outlook
On the basis of region, the sustained release excipients market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Europe region acquired the highest revenue share in the sustained release excipients market in 2021. Increased R&D efforts and the existence of significant pharmaceutical businesses in the area are credited with the region's success. Due to patent expiration dates and the subsequent entry of generics, it is predicted that the region will continue to grow over the forecast period at a profitable rate.The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include BASF SE, International Flavors & Fragrances, Inc., Ashland Global Holdings Inc., Evonik Industries AG, Croda International Plc, Gattefossé, Merck Group, Pfizer, Inc., Novartis AG and AstraZeneca Plc.
Strategies Deployed in Sustained Release Excipients Market
- 2022-Mar: Evonik unveiled EUDRATEC SoluFlow, a new microparticle technology to improve the solubility of engaged pharmaceutical ingredients in oral drug products. The EUDRATEC SoluFlow is an emulsion-based process innovation that reduces solubility difficulties that cannot be handled by present production technologies. Since more than 70% of contemporary small molecules are insoluble, the product, therefore, encourages the development of novel oral therapeutics in various areas such as cancer, cardiovascular diseases, infectious diseases, and diabetes.
- 2021-Feb: Evonik partnered with BioNTech, a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. Through this partnership, Evonik invested in the short-term elaboration of its specialty lipids manufacturing, which is critical for mRNA-based COVID-19 vaccines. The partnership allowed Evonik to participate in increasing the reserve security of the Pfizer-BioNTech COVID-19 vaccine.
- 2020-Nov: Croda partnered with Pfizer, a leading research-based biopharmaceutical company. Under this partnership, Croda would provide lipid-based excipients to Pfizer for the development of mRNA-based COVID-19 vaccine prospects. The inactive components would be manufactured by Avanti Polar Lipids, a high-purity lipids firm that Croda acquired earlier.
- 2020-Sep: Evonik acquired the Lactel business, a subsidiary of Durect Corporation. With this acquisition, Evonik aimed to bolster its in healthcare solutions and its position as a leading CDMO for drug delivery solutions throughout the world. The acquisition marked a prominent step in the development strategy of the life-science unit of nutrition & care of the company.
- 2020-Jul: Croda International took over Avanti Polar Lipids, a knowledge-intensive leader in lipid-based drug delivery technologies for next-generation pharmaceuticals. Through the acquisition, Croda strengthened its drug delivery expertise. Avanti's innovative methodology and expertise are supportive of Croda's abilities in drug delivery systems, vaccine adjuvants, and immunotherapy. The acquisition doubled Croda's research and development (R&D) credentials in drug delivery. Additionally, Avanti also supplied a medium to market Croda's components for initial-stage pharmaceutical study in both retail and academic organizations worldwide.
- 2020-Jun: Evonik introduced the RESOMER Precise platform. The platform equips custom functional polymeric excipients to enable pharmaceutical businesses to manage the release profile of their parenteral drug products to formerly unattainable level of precision and accuracy. The RESOMER platform is facilitated by exceptional and highly sophisticated process technology. The platform assists to optimize drug product resilience and thereby further lessens regulatory risk for a degree of complex parenteral drug products.
Scope of the Study
By Route of Administration
- Oral
- Transdermal
- Vaginal
- Intravenous
- Ophthalmic
- Subcutaneous
- Intramuscular
- Others
By Product
- Polymers
- Minerals
- Sugars
- Gelatin & Chitosan
- Others
By Technology
- Targeted Delivery
- Implants
- Wurster Technique
- Transdermal
- Micro Encapsulation
- Coacervation & Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- BASF SE
- International Flavors & Fragrances, Inc.
- Ashland Global Holdings Inc.
- Evonik Industries AG
- Croda International Plc
- Gattefossé
- Merck Group
- Pfizer, Inc.
- Novartis AG
- AstraZeneca Plc
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Global Sustained Release Excipients Market by Route of Administration
Chapter 5. Global Sustained Release Excipients Market by Product
Chapter 6. Global Sustained Release Excipients Market by Technology
Chapter 7. Global Sustained Release Excipients Market by Region
Chapter 8. Company Profiles
Companies Mentioned
- BASF SE
- International Flavors & Fragrances, Inc.
- Ashland Global Holdings Inc.
- Evonik Industries AG
- Croda International Plc
- Gattefossé
- Merck Group
- Pfizer, Inc.
- Novartis AG
- AstraZeneca Plc
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 278 |
| Published | October 2022 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 1087 Million |
| Forecasted Market Value ( USD | $ 1890 Million |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
